Joerg Albrecht
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Joerg Albrecht has a total of 77 co-authors. Here are the top co-authors by number of shared publications:
- Sascha Gerdes
Psoriasis Center Kiel, Department of Dermatology University Medical Center Schleswig‐Holstein, Campus Kiel Kiel Germany
6 shared publications Michael Bigby
Department of Dermatology, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston, Massachusetts
5 shared publications- O.N. Kramer
Medical School, University of Illinois, Chicago, IL, U.S.A.
4 shared publications A. Nast
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology, Venerology und Allergy, Division of Evidence-Based Medicine (dEBM)Department of Dermatology, Charité, Berlin
2 shared publicationsDamilola Oladinni
A.T. Still University School of Osteopathic Medicine in Arizona, Mesa, Arizona
2 shared publicationsIbrahim Maghari
Department of Medicine, Cook County Health , Chicago, IL , USA
2 shared publications
Latest Publications
- 20 April 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (2) , 534-535
Isotretinoin in jail or prison
- 20 April 2026
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 95 (2) , 534-535
Isotretinoin in jail or prison
- Open Access
- 27 September 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 66, 80-83
Oral plasma cell mucositis
- 27 September 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 66, 80-83
Open AccessOral plasma cell mucositis
- Open Access
- 12 March 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 60, 157-159
Hemorrhagic bullae on bilateral lower extremities
- 12 March 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 60, 157-159
Open AccessHemorrhagic bullae on bilateral lower extremities
- Open Access
- 29 January 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 61, 75-77
Angioinvasive Scopulariopsis infection
- 29 January 2025
- Published by Elsevier in JAAD Case Reports
- Vol. 61, 75-77
Open AccessAngioinvasive Scopulariopsis infection
- 25 November 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (5) , 787-788
A reassuringly routine trial
Joerg Albrecht; A reassuringly routine trial, British Journal of Dermatology, , ljae468, https://doi.org/10.1093/bjd/ljae468
- 25 November 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 192 (5) , 787-788
A reassuringly routine trial
Joerg Albrecht; A reassuringly routine trial, British Journal of Dermatology, , ljae468, https://doi.org/10.1093/bjd/ljae468
- 23 May 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (3) , 451-453
Hidradenitis suppurativa, systemic inflammatory response syndrome and sepsis: a database study
Hidradenitis suppurativa (HS) has unclear pathophysiology and aetiology, but it is not an infectious disease. However, HS is frequently mistaken for an infection and patients with HS are treated for recurrent bacterial abscesses or admitted for sepsis. A systematic literature search that is published as a separate paper did not identify an index case that demonstrates that sepsis can originate in an HS lesion. However, because patients with HS get admitted for sepsis anyway, we wanted to characterize them.
- 23 May 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (3) , 451-453
Hidradenitis suppurativa, systemic inflammatory response syndrome and sepsis: a database study
Hidradenitis suppurativa (HS) has unclear pathophysiology and aetiology, but it is not an infectious disease. However, HS is frequently mistaken for an infection and patients with HS are treated for recurrent bacterial abscesses or admitted for sepsis. A systematic literature search that is published as a separate paper did not identify an index case that demonstrates that sepsis can originate in an HS lesion. However, because patients with HS get admitted for sepsis anyway, we wanted to characterize them.
- 18 April 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (3) , 449-450
Hidradenitis suppurativa (HS), systemic inflammatory response syndrome and sepsis, sepsis caused by HS: an empty systematic review
Dear Editor, Hidradenitis suppurativa (HS) is chronic recurrent noninfectious disease with unclear pathophysiology and aetiology. As a noninfectious disease, HS cannot cause sepsis. However, HS leads to more than 2500 admissions for sepsis in the USA per year.1 To resolve this contradiction we conducted a systematic review of sepsis caused by HS. A comprehensive search for case reports or series of sepsis in patients with HS in the medical literature was done using EMBASE (Elsevier) and MEDLINE, via PUBMED, from origin to 11 October 2022. We included papers that described a case of sepsis or SIRS (systemic inflammatory response syndrome) thought to be due to HS. Cases of sepsis secondary to HS treatment were excluded. The PRISMA diagram and full search strategy is available from the authors on request.2 To categorize the patients’ clinical status within included papers, we used the SIRS and ‘quick sequential organ failure assessment’ (qSOFA) criteria.3
- 18 April 2024
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 191 (3) , 449-450
Hidradenitis suppurativa (HS), systemic inflammatory response syndrome and sepsis, sepsis caused by HS: an empty systematic review
Dear Editor, Hidradenitis suppurativa (HS) is chronic recurrent noninfectious disease with unclear pathophysiology and aetiology. As a noninfectious disease, HS cannot cause sepsis. However, HS leads to more than 2500 admissions for sepsis in the USA per year.1 To resolve this contradiction we conducted a systematic review of sepsis caused by HS. A comprehensive search for case reports or series of sepsis in patients with HS in the medical literature was done using EMBASE (Elsevier) and MEDLINE, via PUBMED, from origin to 11 October 2022. We included papers that described a case of sepsis or SIRS (systemic inflammatory response syndrome) thought to be due to HS. Cases of sepsis secondary to HS treatment were excluded. The PRISMA diagram and full search strategy is available from the authors on request.2 To categorize the patients’ clinical status within included papers, we used the SIRS and ‘quick sequential organ failure assessment’ (qSOFA) criteria.3
- 23 December 2023
- Published by Elsevier in Clinics in Dermatology
- Vol. 42 (2) , 180-191
Sexually transmitted diseases and HIV in transgender patients
- 23 December 2023
- Published by Elsevier in Clinics in Dermatology
- Vol. 42 (2) , 180-191
Sexually transmitted diseases and HIV in transgender patients
- 1 January 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 88 (1) , e31-E31
Rifampin and clindamycin are safe long-term: Response to “North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management”
- 1 January 2023
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 88 (1) , e31-E31
Rifampin and clindamycin are safe long-term: Response to “North American clinical management guidelines for hidradenitis suppurativa: A publication from the United States and Canadian Hidradenitis Suppurativa Foundations Part II: Topical, intralesional, and systemic medical management”
- 1 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (6) , 857-865
Is routine laboratory testing in healthy young patients taking isotretinoin necessary: a critically appraised topic
Summary: Clinical question: Is monitoring of liver function, lipids and full blood count necessary in healthy people taking isotretinoin?Background: Routine blood testing was recommended in the original licence for Roaccutane™ (isotretinoin) in 1983. In recent years, less frequent monitoring has been suggested by various authors.Data sources: We performed four individual systematic searches of the MEDLINE database, via PubMed, from origin to 2 May 2021, supplemented by a hand search of all references in the identified papers.Study selection: Inclusion criteria were any description of clinical symptoms, laboratory abnormalities and/or physical findings, and any paper that explicitly described the patients as asymptomatic, during treatment with oral isotretinoin.Data extraction: Two independent reviewers (J.A. and D.J.) assessed articles for eligibility of inclusion. Evaluation of the data was done also by two of the authors (A.A., D.J. and J.A.) for each section, with the aim to use the presented evidence including guidelines, databases, case series, case reports, cohort studies and randomized clinical trials to delineate the clinical presentation and frequency of adverse events that might be amenable to laboratory monitoring.Results: We identified 407 papers in our searches and reviewed 125 papers in four sections. Overall, reported adverse events were very rare (< 1 in 10 000) and were either idiosyncratic or not preventable by monitoring, accompanied by symptoms, or seen in identifiable predisposed individuals who might benefit from monitoring because of pre-existing conditions.Recommendation for clinical care: We could not find evidence to support the benefit of monitoring to detect adverse events. We suggest that in healthy young people laboratory monitoring for oral isotretinoin is unnecessary and risks detecting nonserious biochemical abnormalities. However, we recognize that new information about adverse events may change that recommendation.
- 1 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 187 (6) , 857-865
Is routine laboratory testing in healthy young patients taking isotretinoin necessary: a critically appraised topic
Summary: Clinical question: Is monitoring of liver function, lipids and full blood count necessary in healthy people taking isotretinoin?Background: Routine blood testing was recommended in the original licence for Roaccutane™ (isotretinoin) in 1983. In recent years, less frequent monitoring has been suggested by various authors.Data sources: We performed four individual systematic searches of the MEDLINE database, via PubMed, from origin to 2 May 2021, supplemented by a hand search of all references in the identified papers.Study selection: Inclusion criteria were any description of clinical symptoms, laboratory abnormalities and/or physical findings, and any paper that explicitly described the patients as asymptomatic, during treatment with oral isotretinoin.Data extraction: Two independent reviewers (J.A. and D.J.) assessed articles for eligibility of inclusion. Evaluation of the data was done also by two of the authors (A.A., D.J. and J.A.) for each section, with the aim to use the presented evidence including guidelines, databases, case series, case reports, cohort studies and randomized clinical trials to delineate the clinical presentation and frequency of adverse events that might be amenable to laboratory monitoring.Results: We identified 407 papers in our searches and reviewed 125 papers in four sections. Overall, reported adverse events were very rare (< 1 in 10 000) and were either idiosyncratic or not preventable by monitoring, accompanied by symptoms, or seen in identifiable predisposed individuals who might benefit from monitoring because of pre-existing conditions.Recommendation for clinical care: We could not find evidence to support the benefit of monitoring to detect adverse events. We suggest that in healthy young people laboratory monitoring for oral isotretinoin is unnecessary and risks detecting nonserious biochemical abnormalities. However, we recognize that new information about adverse events may change that recommendation.